YieldMax AMD Option Income Strategy ETF vs Axogen Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.9, while Axogen Inc trades at $49.1 (market cap $2.61B). The key difference: Axogen Inc is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | AXGN | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.52 | $48.48 |
52-Week Low | $29.80 | $14.16 |
Market Cap | — | $2.61B |
Enterprise Value | — | $2.52B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
Trailing returns across standard periods
Latest headlines on both assets
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →